Mantle Cell Lymphoma Clinical Trials

49 studies are recruiting for mantle cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. SynKIR-310 for Relapsed/Refractory B-NHL

   This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado

   Locations

   5 in total

   Run by

   Verismo Therapeutics

   See if you can join NCT06544265 on ClinicalTrials.gov

2. Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

   This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Univ of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida

   Locations

   3 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06553872 on ClinicalTrials.gov

3. CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

   This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclopho…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Marcela V. Maus, M.D.,Ph.D.

   See if you can join NCT06026319 on ClinicalTrials.gov

4. Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

   This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   2 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06572618 on ClinicalTrials.gov

5. Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

   This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

   Stage

   Not phased

   Ages

   Any age

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06151730 on ClinicalTrials.gov

6. Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

   This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05432635 on ClinicalTrials.gov

7. BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

   This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL). T…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   7 in total

   Run by

   Christine Ryan

   See if you can join NCT06854003 on ClinicalTrials.gov

8. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

   This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Univerisity, Durham, North Carolina

   Locations

   4 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04775745 on ClinicalTrials.gov

9. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

10. CONFIRM: Magnetic Resonance Guided Radiation Therapy

    This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04368702 on ClinicalTrials.gov

11. Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

    This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blo…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT04883437 on ClinicalTrials.gov

12. Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

    This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific monoclonal antibodies. It works by killing cancer cells. A …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06357676 on ClinicalTrials.gov

13. Avo In R/R And Previously Untreated MCL

    This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    3 in total

    Run by

    Austin I Kim

    See if you can join NCT04855695 on ClinicalTrials.gov

14. Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

    This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04223765 on ClinicalTrials.gov

15. Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acala…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06054776 on ClinicalTrials.gov

16. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St Vincent's Hospital, Darlinghurst, New South Wales

    Locations

    16 in total

    Run by

    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

17. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC Irvine Health, Orange, California

    Locations

    13 in total

    Run by

    Carna Biosciences, Inc.

    See if you can join NCT05602363 on ClinicalTrials.gov

18. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Kansas, Westwood, Kansas

    Locations

    7 in total

    Run by

    CRISPR Therapeutics AG

    See if you can join NCT05643742 on ClinicalTrials.gov

19. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

20. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

21. Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

    The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    Alvaro Alencar, MD

    See if you can join NCT06029309 on ClinicalTrials.gov

22. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

23. Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania

    Run by

    John Lister

    See if you can join NCT05281809 on ClinicalTrials.gov

24. Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

    In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford Cancer Center, Palo Alto, California

    Run by

    Adaptive Biotechnologies

    See if you can join NCT05255354 on ClinicalTrials.gov